Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MED21 (ImmuneEditome ID:9412)

1. Gene summary of enriched editing regions for MED21

Gene summary

Gene information	Gene symbol	MED21
	Gene ID	9412
	GeneSynonyms	SRB7\|SURB7\|hSrb7
	GeneCytomap	12p11.23
	GeneType	protein-coding
	GeneDescription	mediator of RNA polymerase II transcription subunit 21\|RNA polymerase II holoenzyme component SRB7\|RNAPII complex component SRB7\|SRB7 suppressor of RNA polymerase B homolog
	GeneModificationdate	20230329
	UniprotID	Q13503;F5GZQ1;F5H872
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr12:27030134-27031084:+	ENST00000546323.4	ENSG00000152944.7	MED21	exonic	AluJr,ERVL-E-int,L1MDa,AluSp	chr12:27030134-27031084:+.alignment
chr12:27034105-27035204:+	ENST00000538186.4	ENSG00000152944.7	MED21	ncRNA_intronic	A-rich,AluJb,AluJo,AluSq2	chr12:27034105-27035204:+.alignment
chr12:27039013-27039906:+	ENST00000538186.4	ENSG00000152944.7	MED21	ncRNA_intronic	AluSg,AluSc8,AluSp	chr12:27039013-27039906:+.alignment

Top

2. Tumor-specific enriched editing regions for MED21

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr12:27030134-27031084:+	BRCA	EER	3.4487e-02
chr12:27034105-27035204:+	BRCA	EER	6.3842e-05
ENSG00000152944.7,MED21	BRCA	EAG	1.5923e-04
ENSG00000152944.7,MED21	KICH	EAG	4.7136e-02
chr12:27034105-27035204:+	LUAD	EER	1.6242e-02
ENSG00000152944.7,MED21	LUAD	EAG	4.6652e-02
chr12:27034105-27035204:+	LUSC	EER	2.7447e-02
chr12:27030134-27031084:+	PRAD	EER	4.6030e-04
chr12:27034105-27035204:+	THCA	EER	2.6713e-05

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr12:27034105-27035204:+	BLCA	Path	EER	4.2458e-02	4.1871e-03	0.2618
chr12:27034105-27035204:+	PAAD	Path	EER	4.5325e-02	2.0589e-02	0.2935

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr12:27034105-27035204:+	PAAD	EER	4.0706e-02	3.8835e-02	1.7160e+01

Top

3. Enriched editing regions and immune related genes for MED21

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for MED21

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr12:27034105-27035204:+

ESCA

EER

ENSG00000186470.9

chr6

26370518:26370603:26372896:26373037:26373275:26373296

0.2729

4.3719e-02

1.7350e-06

0.4396

BTN3A2

Macrophages_M2

GSVA_HALLMARK_INFLAMMATORY_RESPONSE

More results

Top

5. Enriched editing regions and immune infiltration for MED21

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr12:27034105-27035204:+	ACC	EER	T_cells_CD4_memory_activated	2.6535e-02	-0.4188
chr12:27034105-27035204:+	BLCA	EER	T_cells_CD4_memory_resting	5.5196e-03	0.2550
ENSG00000152944.7,MED21	BLCA	EAG	T_cells_gamma_delta	2.1822e-02	-0.1924
chr12:27030134-27031084:+	BRCA	EER	T_cells_CD4_naive	8.3978e-04	0.1578
chr12:27034105-27035204:+	BRCA	EER	Monocytes	7.9899e-03	-0.0973
ENSG00000152944.7,MED21	BRCA	EAG	T_cells_follicular_helper	3.1576e-02	0.0766
chr12:27034105-27035204:+	CESC	EER	Eosinophils	2.1429e-02	-0.2016
chr12:27034105-27035204:+	COAD	EER	Eosinophils	3.2265e-02	0.2492
chr12:27034105-27035204:+	ESCA	EER	Mast_cells_activated	9.8661e-04	0.2655
ENSG00000152944.7,MED21	ESCA	EAG	Mast_cells_activated	1.6758e-02	0.1938
chr12:27034105-27035204:+	GBM	EER	Mast_cells_resting	4.3816e-02	-0.3246
ENSG00000152944.7,MED21	GBM	EAG	Mast_cells_resting	2.9319e-02	-0.3148
chr12:27034105-27035204:+	HNSC	EER	NK_cells_resting	1.0433e-04	0.2247
ENSG00000152944.7,MED21	HNSC	EAG	NK_cells_resting	8.8227e-03	0.1457
ENSG00000152944.7,MED21	KICH	EAG	T_cells_CD4_memory_resting	1.4029e-02	-0.4175
chr12:27034105-27035204:+	KIRC	EER	B_cells_memory	4.2391e-03	0.1836
ENSG00000152944.7,MED21	KIRC	EAG	B_cells_memory	2.7842e-03	0.1855
chr12:27034105-27035204:+	LAML	EER	Monocytes	2.4363e-02	0.1923
ENSG00000152944.7,MED21	LAML	EAG	Monocytes	4.5029e-03	0.2354
chr12:27034105-27035204:+	LGG	EER	Monocytes	2.6888e-02	0.1527
ENSG00000152944.7,MED21	LGG	EAG	Dendritic_cells_resting	2.6096e-02	-0.1316
chr12:27034105-27035204:+	LIHC	EER	Macrophages_M1	9.5068e-03	0.4208
ENSG00000152944.7,MED21	LIHC	EAG	Macrophages_M1	4.6117e-03	0.3868
ENSG00000152944.7,MED21	LUAD	EAG	T_cells_regulatory_(Tregs)	4.3533e-02	0.1335
ENSG00000152944.7,MED21	LUSC	EAG	Eosinophils	3.3428e-02	-0.1222
chr12:27034105-27035204:+	OV	EER	NK_cells_activated	2.1264e-02	0.1684
ENSG00000152944.7,MED21	PCPG	EAG	Mast_cells_activated	1.5446e-02	-0.2620
chr12:27030134-27031084:+	PRAD	EER	T_cells_gamma_delta	2.2361e-03	0.3116
ENSG00000152944.7,MED21	SARC	EAG	Monocytes	7.2029e-03	0.2462
chr12:27034105-27035204:+	SKCM	EER	B_cells_memory	1.2753e-02	0.2520
ENSG00000152944.7,MED21	SKCM	EAG	B_cells_memory	1.2803e-02	0.2153
chr12:27034105-27035204:+	STAD	EER	T_cells_CD8	1.1919e-02	0.1429
chr12:27039013-27039906:+	STAD	EER	Mast_cells_activated	2.6701e-02	-0.4112
ENSG00000152944.7,MED21	STAD	EAG	T_cells_CD8	5.1788e-04	0.1901
chr12:27034105-27035204:+	TGCT	EER	Macrophages_M2	3.3260e-02	-0.2164
ENSG00000152944.7,MED21	TGCT	EAG	Macrophages_M0	3.2726e-02	0.2170
chr12:27034105-27035204:+	THCA	EER	T_cells_CD4_memory_resting	2.7044e-02	-0.1418
chr12:27034105-27035204:+	THYM	EER	T_cells_CD4_memory_resting	6.2362e-03	0.4106
ENSG00000152944.7,MED21	THYM	EAG	B_cells_memory	1.6694e-02	0.3439
chr12:27034105-27035204:+	UCEC	EER	T_cells_regulatory_(Tregs)	2.9231e-04	0.5762

Top

6. Enriched editing regions and immune gene sets for MED21

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000152944.7,MED21	ACC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	4.1963e-02	0.3736
chr12:27034105-27035204:+	BLCA	GSVA_HALLMARK_MYOGENESIS	EER	1.3946e-02	0.2268
chr12:27034105-27035204:+	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	4.3058e-06	0.1678
ENSG00000152944.7,MED21	BRCA	GSVA_HALLMARK_DNA_REPAIR	EAG	6.2358e-05	0.1421
chr12:27030134-27031084:+	BRCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	5.4205e-03	-0.1316
ENSG00000152944.7,MED21	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	9.0264e-03	0.2111
chr12:27034105-27035204:+	CESC	GSVA_HALLMARK_COMPLEMENT	EER	2.1391e-02	0.2017
ENSG00000152944.7,MED21	COAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	4.4864e-02	0.2052
chr12:27034105-27035204:+	ESCA	GSVA_HALLMARK_COAGULATION	EER	1.1340e-02	0.2056
ENSG00000152944.7,MED21	ESCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.2107e-02	-0.2031
chr12:27034105-27035204:+	GBM	GSVA_HALLMARK_PEROXISOME	EER	2.1965e-03	0.4759
ENSG00000152944.7,MED21	GBM	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	1.2025e-02	0.3598
ENSG00000152944.7,MED21	HNSC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	4.8419e-02	0.1101
chr12:27034105-27035204:+	HNSC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.9382e-02	0.1365
ENSG00000152944.7,MED21	KICH	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	6.6077e-03	0.4568
chr12:27034105-27035204:+	KICH	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.5386e-02	-0.4314
chr12:27034105-27035204:+	KIRC	GSVA_HALLMARK_MYC_TARGETS_V1	EER	3.5376e-03	0.1872
ENSG00000152944.7,MED21	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	9.6955e-03	0.1608
chr12:27034105-27035204:+	KIRP	GSVA_HALLMARK_DNA_REPAIR	EER	6.8945e-03	0.3055
chr12:27034105-27035204:+	LAML	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.5898e-02	0.2057
ENSG00000152944.7,MED21	LAML	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.2727e-03	0.2660
ENSG00000152944.7,MED21	LGG	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	2.2985e-03	-0.1796
chr12:27034105-27035204:+	LGG	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.4630e-04	-0.2591
ENSG00000152944.7,MED21	LIHC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	3.0941e-02	0.2996
chr12:27034105-27035204:+	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.5623e-03	0.4671
ENSG00000152944.7,MED21	LUAD	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	4.6811e-03	-0.1863
chr12:27034105-27035204:+	LUAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	4.7567e-02	0.1491
chr12:27034105-27035204:+	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.9582e-02	0.1240
ENSG00000152944.7,MED21	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	4.4969e-02	0.1153
chr12:27034105-27035204:+	OV	GSVA_HALLMARK_SPERMATOGENESIS	EER	2.6884e-02	-0.1619
ENSG00000152944.7,MED21	PAAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	2.8429e-02	-0.2515
ENSG00000152944.7,MED21	PRAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.2393e-02	0.1707
chr12:27030134-27031084:+	PRAD	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	8.8253e-04	-0.3374
chr12:27034105-27035204:+	PRAD	GSVA_HALLMARK_NOTCH_SIGNALING	EER	3.1523e-02	0.1626
chr12:27034105-27035204:+	SARC	GSVA_HALLMARK_HYPOXIA	EER	3.4958e-02	0.2091
ENSG00000152944.7,MED21	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	2.4439e-03	-0.2607
chr12:27034105-27035204:+	SKCM	GSVA_HALLMARK_MTORC1_SIGNALING	EER	2.6675e-03	-0.3017
chr12:27034105-27035204:+	STAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	5.0521e-04	0.1967
chr12:27039013-27039906:+	STAD	GSVA_HALLMARK_P53_PATHWAY	EER	1.6583e-03	0.5580
chr12:27030134-27031084:+	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.2822e-04	-0.2695
ENSG00000152944.7,MED21	STAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.6160e-03	-0.1652
chr12:27034105-27035204:+	TGCT	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.7379e-04	0.3722
ENSG00000152944.7,MED21	TGCT	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.6366e-04	0.3625
ENSG00000152944.7,MED21	THCA	GSVA_HALLMARK_APICAL_JUNCTION	EAG	8.5150e-03	-0.1564
chr12:27034105-27035204:+	THCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.9431e-03	0.1900
chr12:27034105-27035204:+	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.9769e-02	-0.3148
ENSG00000152944.7,MED21	THYM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	4.7179e-03	-0.4011
chr12:27034105-27035204:+	UCEC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.2392e-02	-0.3624

Top

7. Enriched editing regions and drugs for MED21

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr12:27034105-27035204:+	ACC	GW.441756	EER	9.6192e-03	0.4807
ENSG00000152944.7,MED21	ACC	GW.441756	EAG	2.5411e-03	0.5309
ENSG00000152944.7,MED21	BLCA	Imatinib	EAG	3.6082e-03	-0.2427
chr12:27034105-27035204:+	BLCA	Imatinib	EER	6.7189e-04	-0.3099
chr12:27034105-27035204:+	BRCA	DMOG	EER	1.7590e-03	0.1147
ENSG00000152944.7,MED21	BRCA	CCT007093	EAG	1.5023e-02	0.0866
chr12:27030134-27031084:+	BRCA	MG.132	EER	1.5706e-03	0.1496
chr12:27034105-27035204:+	CESC	FH535	EER	2.4722e-03	0.2633
ENSG00000152944.7,MED21	CESC	FH535	EAG	3.5608e-02	0.1706
ENSG00000152944.7,MED21	COAD	Bicalutamide	EAG	4.8451e-02	-0.2020
ENSG00000152944.7,MED21	ESCA	KU.55933	EAG	3.7138e-04	-0.2860
chr12:27034105-27035204:+	ESCA	Embelin	EER	2.5035e-09	0.4613
chr12:27034105-27035204:+	GBM	JW.7.52.1	EER	8.0983e-03	-0.4180
ENSG00000152944.7,MED21	GBM	JW.7.52.1	EAG	1.2374e-03	-0.4526
chr12:27034105-27035204:+	HNSC	CCT018159	EER	3.3856e-02	-0.1240
ENSG00000152944.7,MED21	HNSC	DMOG	EAG	3.9358e-03	-0.1603
ENSG00000152944.7,MED21	KICH	Cisplatin	EAG	2.1432e-03	0.5084
chr12:27034105-27035204:+	KICH	AZD6244	EER	8.2471e-03	-0.4659
chr12:27034105-27035204:+	KIRC	BAY.61.3606	EER	7.3490e-05	0.2526
ENSG00000152944.7,MED21	KIRC	GDC.0449	EAG	1.6757e-04	0.2327
chr12:27034105-27035204:+	KIRP	AZD6482	EER	4.5985e-03	0.3197
ENSG00000152944.7,MED21	LAML	CCT007093	EAG	9.5094e-05	0.3194
chr12:27034105-27035204:+	LAML	CCT007093	EER	6.3866e-03	0.2319
chr12:27034105-27035204:+	LGG	Docetaxel	EER	7.7102e-04	0.2303
ENSG00000152944.7,MED21	LGG	AZD6482	EAG	2.7805e-02	-0.1301
chr12:27034105-27035204:+	LIHC	GSK.650394	EER	2.6624e-02	0.3644
ENSG00000152944.7,MED21	LIHC	FTI.277	EAG	7.1868e-03	0.3685
ENSG00000152944.7,MED21	LUAD	AUY922	EAG	5.7160e-03	-0.1821
chr12:27034105-27035204:+	LUAD	AUY922	EER	7.8616e-04	-0.2501
chr12:27034105-27035204:+	LUSC	CI.1040	EER	1.4548e-02	-0.1470
ENSG00000152944.7,MED21	LUSC	AZD6244	EAG	3.5851e-02	-0.1206
ENSG00000152944.7,MED21	OV	AZD8055	EAG	4.0307e-02	0.1462
chr12:27034105-27035204:+	OV	AZD8055	EER	2.0916e-03	0.2236
chr12:27034105-27035204:+	PAAD	Elesclomol	EER	3.5341e-02	0.2678
ENSG00000152944.7,MED21	PAAD	CEP.701	EAG	2.5441e-02	0.2580
ENSG00000152944.7,MED21	PCPG	JNK.Inhibitor.VIII	EAG	1.5176e-03	-0.3388
chr12:27034105-27035204:+	PCPG	EHT.1864	EER	2.5357e-02	-0.2672
chr12:27034105-27035204:+	PRAD	BMS.536924	EER	3.6992e-03	-0.2183
ENSG00000152944.7,MED21	PRAD	Axitinib	EAG	6.3885e-03	0.1859
chr12:27030134-27031084:+	PRAD	CMK	EER	1.2515e-02	-0.2567
ENSG00000152944.7,MED21	READ	AZD8055	EAG	6.7072e-03	-0.4627
ENSG00000152944.7,MED21	SARC	AP.24534	EAG	3.1527e-02	0.1981
chr12:27034105-27035204:+	SARC	Embelin	EER	1.2157e-02	0.2475
chr12:27034105-27035204:+	SKCM	BX.795	EER	4.0369e-03	-0.2894
ENSG00000152944.7,MED21	SKCM	MG.132	EAG	2.2565e-04	0.3158
chr12:27030134-27031084:+	STAD	AZD.2281	EER	3.5685e-03	-0.2077
ENSG00000152944.7,MED21	STAD	BAY.61.3606	EAG	4.6088e-05	0.2223
chr12:27039013-27039906:+	STAD	AZD6244	EER	3.9420e-02	-0.3846
chr12:27034105-27035204:+	STAD	BAY.61.3606	EER	4.0524e-08	0.3060
chr12:27034105-27035204:+	TGCT	FTI.277	EER	5.2107e-03	0.2816
ENSG00000152944.7,MED21	TGCT	FTI.277	EAG	1.0178e-02	0.2598
ENSG00000152944.7,MED21	THCA	Gemcitabine	EAG	2.4385e-03	0.1798
chr12:27034105-27035204:+	THCA	AG.014699	EER	1.5807e-02	0.1547
ENSG00000152944.7,MED21	THYM	AZD6244	EAG	1.2919e-06	-0.6343
chr12:27034105-27035204:+	THYM	GW.441756	EER	1.5971e-02	-0.3654
chr12:27034105-27035204:+	UCEC	CEP.701	EER	3.7587e-06	-0.6941
ENSG00000152944.7,MED21	UCEC	DMOG	EAG	4.8526e-03	0.4083

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType